On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders
So this is where PI3k cancer drugs have fallen to.
Infinity Pharmaceuticals, which once touted its lead drug duvelisib as a blockbuster contender, has now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
